Evaluation of p16 and ESR1 promoter methylation in blood using real-time PCR appears to be very useful for lung cancer diagnosis

Presence of estrogen and/or progesterone expression in neuroendocrine tumors involving the lung should not exclude a primary pulmonary neoplasm.

Nuclear localization of P-ser118-ER alpha provides one explanation for sex-dependent differences in E(2)-genomic responses in lung adenocarcinoma cell lines.

Estrogen receptor alpha and beta expression distinguishes a subset of NSCLC that has defined clinicopathologic and genetic features. In lung adenocarcinoma, estrogen receptor alpha expression correlates with EGFR mutations.

Data show that the L858R mutation of EGFR is associated with SNP of estrogen biosynthesis and metabolism genes CYP17, CYP19A1, ERalpha, and COMT in never-smoking female lung adenocarcinoma patients.

The median time of survival in patients with lung cancer depending on the expression of ER alpha was 31 months, while for ER beta was 73 months.

Thyroid hormone is shown to induce human lung cancer cell proliferation via crosstalk between integrin alphavbeta3 and ERalpha.

CAV-1 affected cell growth of lung cancer NCI-H446 cell through the interactions with p-ERK1/2, estrogen receptor and progestin receptor

Presence of membrane-bound ERalpha expression together with EGFR mutation was found to be an independent prognostic factor for survival in patients with lung adenocarcinoma, suggesting cross-talk between membrane-bound ERalpha and EGFR mutation.

findings show ESR1 is an independent positive prognostic factor for survival in early-stage non-small cell lung cancer patients; patients with ESR1 high tumors did not benefit from adjuvant chemotherapy

Data show that estrogen receptor 1 (ESR1) mRNA as assessed by qPCR represents a reliable method for detecting ESR1 expression in non-small cell lung cancer (NSCLS) and that ESR1 expression is an independent prognostic factor in metastatic NSCLC.

ERbeta and CXCL12/CXCR4 expression in lung adenocarcinoma depends on sex and hormonal status, which may partly explain the sex and hormonal differences in lung cancer behavior.

ERalpha36 had a high expression mainly in adenocarcinoma and the high expression of ERalpha36 was strongly correlated with more advanced regional lymph node metastasis and poor survival in lung adenocarcinoma

Nuclear ERalpha expression is an independent predictor of recurrence in pT1a lung adenocarcinomas and correlates with poor prognostic immune microenvironments.

Inhibition of ERalpha signaling in prostate cancer cells may be a novel therapeutic strategy to inhibit the osteoblastic lesion development as well as lung metastasis in patients with advanced prostate cancer.

Report a significant survival benefit in lung adenocarcinoma patients with positive expression of one of the investigated hormonal receptors: androgen receptor, estrogen receptor-alpha or progesterone receptor.

Computational analysis of publicly available microarray datasets of non-small cell lung cancer (NSCC) treated with EGFR targeted therapy identified ESR1 and ELAV1 as the most highly ranked hub genes involved in the NSCLC acquired TKI-resistance.

Oestrogen actions contribute to female gender-specific risks in the development of lung carcinoma.